Pharma News - Drug Trials News & Articles

121 Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress Full Text Merck, April 24, 2013

122 A Randomized Phase II Trial of Maintenance Therapy with Sorafenib in Front-line Ovarian Carcinoma Gynecologic Oncology, April 24, 2013    Clinical Article

123 Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process? American Journal of Therapeutics, April 24, 2013    Evidence Based Medicine    Review Article

124 Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy Clinical and Translational Oncology, April 24, 2013    Clinical Article

125 Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C Full Text Merck, April 23, 2013

126 Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction in Patients With Preserved Ejection Fraction The Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) Trial. Circulation, April 23, 2013    Clinical Article

127 Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors Investigational New Drugs, April 23, 2013    Clinical Article

128 Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older Cancer, April 23, 2013    Clinical Article

129 A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine, on Actual Driving and Cognition Clinical Pharmacology & Therapeutics, April 23, 2013    Clinical Article

130 Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer--Study BES 06 Targeted Oncology, April 23, 2013    Clinical Article

131 The Efficacy of Rivaroxaban in Patients With Atrial Fibrillation American Journal of Therapeutics, April 23, 2013    Clinical Article

132 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Full Text Teva Pharmaceutical Industries, April 22, 2013

133 Results of Phase II/III Clinical Trial of Ibandronate Sodium Hydrate Injection, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented Full Text Chugai Pharmaceutical Co., April 22, 2013

134 DCDT2980S, an anti-CD22-Monomethyl Auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkins Lymphoma Molecular Cancer Therapeutics, April 22, 2013    Clinical Article

135 FDA Advisory Committee recommends approval of BREO ELLIPT for the treatment of COPD Full Text GlaxoSmithKline, April 19, 2013

136 Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas Neuro-Oncology, April 19, 2013    Review Article

137 Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551) in Mechanically Ventilated Patients with Gram-negative Pneumonia Full Text Bayer HealthCare Pharmaceuticals, April 19, 2013

138 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Full Text Teva Pharmaceutical Industries, April 19, 2013

139 Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Full Text Sarepta Therapeutics, April 19, 2013

140 Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop Full Text Array BioPharma, April 19, 2013

1 Statement on FOSAMAX (alendronate sodium) Product Liability Trial Merck, March 12, 2013    Free full text

2 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Teva Pharmaceutical Industries, April 22, 2013    Free full text

3 CEL-SCI Corporation Provides Update on Phase III Clinical Trial CEL-SCI, April 24, 2013    Free full text

4 FDA Releases Guidance on Non-Penicillin Beta-Lactam Drugs BioPharm International, April 18, 2013    Free full text

5 Merck Provides Update on IMPROVE-IT Trial Merck, March 13, 2013    Free full text

6 Pfizer's Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer Pfizer, April 15, 2013    Free full text

7 Merck Pays $688 Million to Resolve Vytorin Lawsuits BioPharm International, February 28, 2013    Free full text

8 Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma Clinical Cancer Research, April 8, 2013

9 FDA Approves New Drug Application (NDA) for Tevas Quartette- (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy Teva Pharmaceutical Industries, April 1, 2013    Free full text

10 Interim results evaluate virologic response rates in HCV/HIV co-infected patients treated with faldaprevir Formulary , March 21, 2013    Free full text

11 New Data Show Azilect (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinsons When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy Teva Pharmaceutical Industries, March 21, 2013    Free full text

12 Improving IRBs: A Case Study with Copernicus Group IRB Applied Clinical Trials, March 28, 2013    Free full text

13 BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA BioMarin, April 25, 2013    Free full text

14 Beyond Statins: Lipid Management to Reduce Cardiovascular Risk Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 26, 2013    Evidence Based Medicine    Review Article

15 PhRMA Statement on Clinical Trials and Bad Pharma PhRMA, February 7, 2013    Free full text

16 Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Sarepta Therapeutics, April 19, 2013    Free full text

17 Translating Stem Cells From Laboratory to Clinic BioPharm International, April 18, 2013    Free full text

18 Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy Clinical and Translational Oncology, April 24, 2013

19 Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC) Clinical and Translational Oncology, April 29, 2013

20 Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Sarepta Therapeutics, April 10, 2013    Free full text